Development and validation of HPLC method for ximenynic acid in semisolid dosage formulation
1 Department of pharmaceutical sciences, JJT University, Jhunjhunu- 333001, Rajasthan, India.
2 Vice president clinical research, Clinical Research, Mprex Healthcare, Maharashtra, Pune, India.
Research Article
World Journal of Advanced Research and Reviews, 2023, 17(02), 113–120
Publication history:
Received on 27 December 2022; revised on 01 February 2023; accepted on 04 February 2023
Abstract:
A novel analytical technique and validation study were developed to determine the concentration of ximenynic acid (XMA) in semisolid dosage formulations (SDF) such as cream, gel, lotion, etc. The procedure makes use of reverse-phase high-performance liquid chromatography (HPLC). A Phenomenex Luna Column 5 (4.6 x 250 mm) was used for the analysis, using acetonitrile as the mobile phase, sodium dihydrogen phosphate monohydrate as the stationary phase, and 229 nm detection at 30 degrees Celsius. In spite of the presence of additional compounds, their presence had no effect on the detection of XMA in SDF. As part of validating this HPLC technique, a number of tests were performed to evaluate its specificity, linearity, accuracy, precision, and durability. International Conference on Harmonization standards were used to determine whether the method was adequate (ICH). Because it is simple to implement and produces reproducible results, the presented HPLC approach has the potential to be utilized in industry to standardize herbs and Phytomedicines. Because XMA has the potential to be a game-changing method of treating ageing, its advancement may benefit the pharmaceutical and cosmetics sectors.
Keywords:
Ximenynic acid; Skin Care Medicinal Formulation; HPLC; Validation
Full text article in PDF:
Copyright information:
Copyright © 2023 Author(s) retain the copyright of this article. This article is published under the terms of the Creative Commons Attribution Liscense 4.0